Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagatell, R.
Right arrow Articles by Whitesell, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagatell, R.
Right arrow Articles by Whitesell, L.
Clinical Cancer Research Vol. 6, 3312-3318, August 2000
© 2000 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Induction of a Heat Shock Factor 1-dependent Stress Response Alters the Cytotoxic Activity of Hsp90-binding Agents1

Rochelle Bagatell, Gillian D. Paine-Murrieta, Charles W. Taylor, Elizabeth J. Pulcini, Shiro Akinaga, Ivor J. Benjamin and Luke Whitesell2

Department of Pediatrics, Steele Memorial Children’s Research Center, University of Arizona, Tucson, Arizona 85724 [R. B., E. J. P., L. W.]; Arizona Cancer Center, University of Arizona, Tucson, Arizona [G. D. P-M., C. W. T.]; Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan [S. A.]; and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 [I. J. B.]

In addition to its classic role in the cellular stress response, heat shock protein 90 (Hsp90) plays a critical but less well appreciated role in regulating signal transduction pathways that control cell growth and survival under basal, nonstress conditions. Over the past 5 years, the antitumor antibiotics geldanamycin and radicicol have become recognized as selective Hsp90-binding agents (HBA) with a novel ability to alter the activity of many of the receptors, kinases, and transcription factors involved in these cancer-associated pathways. As a consequence of their interaction with Hsp90, however, these agents also induce a marked cellular heat shock response. To study the mechanism of this response and assess its relevance to the anticancer action of the HBA, we verified that the compounds could activate a reporter construct containing consensus binding sites for heat shock factor 1 (HSF1), the major transcriptional regulator of the vertebrate heat shock response. We then used transformed fibroblasts derived from HSF1 knock-out mice to show that unlike conventional chemotherapeutics, HBA increased the synthesis and cellular levels of heat shock proteins in an HSF1-dependent manner. Compared with transformed fibroblasts derived from wild-type mice, HSF1 knock-out cells were significantly more sensitive to the cytotoxic effects of HBA but not to doxorubicin or cisplatin. Consistent with these in vitro data, we found that systemic administration of an HBA led to marked increases in the level of Hsp72 in both normal mouse tissues and human tumor xenografts. We conclude that HBA are useful probes for studying molecular mechanisms regulating the heat shock response both in cells and in whole animals. Moreover, induction of the heat shock response by HBA will be an important consideration in the clinical application of these drugs, both in terms of modulating their cytotoxic activity as well as monitoring their biological activity in individual patients.




This article has been cited by other articles:


Home page
IOVSHome page
J. Hidalgo-de-Quintana, R. J. Evans, M. E. Cheetham, and J. van der Spuy
The Leber Congenital Amaurosis Protein AIPL1 Functions as Part of a Chaperone Heterocomplex
Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2878 - 2887.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
R. I. Morimoto
Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging
Genes & Dev., June 1, 2008; 22(11): 1427 - 1438.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. Trott, J. D. West, L. Klaic, S. D. Westerheide, R. B. Silverman, R. I. Morimoto, and K. A. Morano
Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted Molecule
Mol. Biol. Cell, March 1, 2008; 19(3): 1104 - 1112.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. C. Arthur, J. D. Lich, R. K. Aziz, M. Kotb, and J. P.-Y. Ting
Heat Shock Protein 90 Associates with Monarch-1 and Regulates Its Ability to Promote Degradation of NF-{kappa}B-Inducing Kinase
J. Immunol., November 1, 2007; 179(9): 6291 - 6296.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K.-M. J. Cheung, A. Kalusa, K. James, et al.
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Mol. Cancer Ther., April 1, 2007; 6(4): 1198 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. J. Weigel, S. M. Blaney, J. M. Reid, S. L. Safgren, R. Bagatell, J. Kersey, J. P. Neglia, S. P. Ivy, A. M. Ingle, L. Whitesell, et al.
A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study
Clin. Cancer Res., March 15, 2007; 13(6): 1789 - 1793.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. K. McCollum, C. J. TenEyck, B. M. Sauer, D. O. Toft, and C. Erlichman
Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism.
Cancer Res., November 15, 2006; 66(22): 10967 - 10975.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. S. Nowakowski, A. K. McCollum, M. M. Ames, S. J. Mandrekar, J. M. Reid, A. A. Adjei, D. O. Toft, S. L. Safgren, and C. Erlichman
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6087 - 6093.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, and L. Neckers
Endoplasmic Reticulum Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 Inhibition by Geldanamycin and Proteasome Inhibition by Velcade
Mol. Cancer Res., September 1, 2006; 4(9): 667 - 681.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Rossi, S. Ciafre, M. Balsamo, P. Pierimarchi, and M. G. Santoro
Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer.
Cancer Res., August 1, 2006; 66(15): 7678 - 7685.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. Yetik-Anacak, T. Xia, C. Dimitropoulou, R. C. Venema, and J. D. Catravas
Effects of hsp90 binding inhibitors on sGC-mediated vascular relaxation
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H260 - H268.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. Thomas, J. M. Harrell, Y. Morishima, H.-M. Peng, W. B. Pratt, and A. P. Lieberman
Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction
Hum. Mol. Genet., June 1, 2006; 15(11): 1876 - 1883.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
S. J. Neal, S. Karunanithi, A. Best, A. K.-C. So, R. M. Tanguay, H. L. Atwood, and J. T. Westwood
Thermoprotection of synaptic transmission in a Drosophila heat shock factor mutant is accompanied by increased expression of Hsp83 and DnaJ-1
Physiol Genomics, May 16, 2006; 25(3): 493 - 501.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Sanderson, M. Valenti, S. Gowan, L. Patterson, Z. Ahmad, P. Workman, and S. A. Eccles
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Mol. Cancer Ther., March 1, 2006; 5(3): 522 - 532.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Zaarur, V. L. Gabai, J. A. Porco Jr., S. Calderwood, and M. Y. Sherman
Targeting Heat Shock Response to Sensitize Cancer Cells to Proteasome and Hsp90 Inhibitors
Cancer Res., February 1, 2006; 66(3): 1783 - 1791.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al.
Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin
Cancer Res., November 15, 2005; 65(22): 10536 - 10544.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. L. Vega and A. De Maio
Increase in Phagocytosis after Geldanamycin Treatment or Heat Shock: Role of Heat Shock Proteins
J. Immunol., October 15, 2005; 175(8): 5280 - 5287.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. J. Turbyville, E.M. K. Wijeratne, L. Whitesell, and A.A. L. Gunatilaka
The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways
Mol. Cancer Ther., October 1, 2005; 4(10): 1569 - 1576.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. D. Westerheide and R. I. Morimoto
Heat Shock Response Modulators as Therapeutic Tools for Diseases of Protein Conformation
J. Biol. Chem., September 30, 2005; 280(39): 33097 - 33100.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al.
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS
J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al.
The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line
Cancer Res., June 1, 2005; 65(11): 4929 - 4938.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. K. Auluck, M. C. Meulener, and N. M. Bonini
Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila
J. Biol. Chem., January 28, 2005; 280(4): 2873 - 2878.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. D. Westerheide, J. D. Bosman, B. N. A. Mbadugha, T. L. A. Kawahara, G. Matsumoto, S. Kim, W. Gu, J. P. Devlin, R. B. Silverman, and R. I. Morimoto
Celastrols as Inducers of the Heat Shock Response and Cytoprotection
J. Biol. Chem., December 31, 2004; 279(53): 56053 - 56060.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Bagatell and L. Whitesell
Altered Hsp90 function in cancer: A unique therapeutic opportunity
Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, J. S. Isaacs, K. S. Bisht, D. Gius, and L. Neckers
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity
Mol. Cancer Ther., May 1, 2004; 3(5): 551 - 566.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. B. Cox and C. A. Miller III
Pharmacological and Genetic Analysis of 90-kDa Heat Shock Isoprotein-Aryl Hydrocarbon Receptor Complexes
Mol. Pharmacol., December 1, 2003; 64(6): 1549 - 1556.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Bagatell, O. Khan, G. Paine-Murrieta, C. W. Taylor, S. Akinaga, and L. Whitesell
Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: A Ligand-independent Approach to Hormonal Therapy of Breast Cancer
Clin. Cancer Res., July 1, 2001; 7(7): 2076 - 2084.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Hostein, D. Robertson, F. DiStefano, P. Workman, and P. Andrew Clarke
Inhibition of Signal Transduction by the Hsp90 Inhibitor 17-Allylamino-17-demethoxygeldanamycin Results in Cytostasis and Apoptosis
Cancer Res., May 1, 2001; 61(10): 4003 - 4009.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.